Loading organizations...
Oxular is a technology company.
Oxular is a clinical-stage retinal therapeutics company developing advanced treatments for ocular diseases. It leverages proprietary formulation and delivery technologies for precise, tissue-specific administration of potent drug products within the eye. This targeted approach enhances treatment efficacy for complex retinal conditions.
The company was co-founded by Thomas Cavanagh and Ronald Yamamoto, stemming from the insight that existing retinal disease treatments often lack precision. Thomas Cavanagh, an experienced ophthalmic pharmaceutical executive, brings deep sector knowledge, driving Oxular's therapeutic development. Their collective expertise focuses on improving drug delivery to specific intraocular spaces.
Oxular's therapies are designed for patients suffering from various retinal ailments, addressing unmet medical needs. The company aims to pioneer advancements in ocular drug delivery, aspiring to improve vision and quality of life for individuals with severe eye conditions. Its vision is to establish new standards in retinal disease management.
Oxular has raised $57.3M across 2 funding rounds.
Oxular has raised $57.3M in total across 2 funding rounds.
Oxular has raised $57.3M in total across 2 funding rounds.
Oxular's investors include Forbion, NeoMed Management, V-Bio Ventures, Hovione Scientia, Imperial Innovations, Christina Takke.
Oxular is a UK-based clinical-stage biotechnology company developing sustained-release therapies for retinal diseases, leveraging proprietary Oxuspheres (biodegradable polymer microspheres) and Oxulumis (suprachoroidal microcatheter delivery system).[1][2][3] It targets conditions like diabetic macular oedema (DMO), retinal vein occlusion (RVO), and uveitis, serving retinal specialists and patients by reducing treatment frequency from frequent injections to potentially once-yearly dosing, addressing high treatment burdens and side effects.[2][3][5] Its lead candidate, OXU-001 (dexamethasone-loaded Oxuspheres), entered Phase 2 trials in October 2024 for DMO, showing promising durability up to 12 months with sustained vision gains and retinal thickness reduction.[3][4] Recently acquired by Regeneron Pharmaceuticals, Oxular's growth momentum peaked with this deal, validating its technology amid advancing clinical progress.[2][3]
Founded in 2014 in Oxford, England, by Tom Cavanagh and Ronald K. Yamamoto, Oxular emerged from expertise in biotechnology focused on retinal drug delivery challenges, particularly reaching small eye spaces for precise targeting.[2][4] The idea stemmed from developing technologies to overcome limitations of existing therapies, like frequent intravitreal injections causing side effects and poor compliance. Early traction built around Oxuspheres and Oxulumis, with pivotal moments including FDA advancements for OXU-001 and the start of the OXEYE Phase 2 trial in 2024, dosing patients to evaluate safety, efficacy, and 52-week durability.[3][4] Backed by Forbion, these milestones led to Regeneron's acquisition announced in early January 2025.[1][2][3]
Oxular rides the wave of advanced drug delivery in ophthalmology, targeting the growing retinal disease market driven by aging populations and rising diabetes prevalence, where DMO and RVO affect millions needing better long-term therapies.[3][4] Timing aligns with momentum in sustained-release platforms, as frequent injections strain healthcare systems; Oxular's suprachoroidal approach influences ecosystem shifts toward less invasive, durable treatments.[2][5] Its acquisition by Regeneron amplifies impact, integrating into a major player's retina portfolio to accelerate trials and commercialization, potentially setting standards for biotech innovation in eye care.[2][3]
Post-acquisition, Oxular's tech will likely advance rapidly under Regeneron, with OXEYE Phase 2 data expected to drive OXU-001 toward Phase 3 and expansion into RVO/uveitis.[3] Trends like AI-optimized delivery and combo therapies will shape its path, evolving its influence from niche innovator to backbone of next-gen retinal treatments. This deal cements Oxular's legacy in solving persistent eye therapy gaps, supercharging its mission for patients and specialists.[2][3]
Oxular has raised $57.3M across 2 funding rounds. Most recently, it raised $37.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $37.0M Series B | Forbion | NeoMed Management, V-Bio Ventures |
| Jul 19, 2016 | $20.3M Series A | Hovione Scientia, Imperial Innovations, NeoMed Management, Christina Takke |